Tramadol Not Working? CYP2D6 Genetics May Be Why

Your doctor prescribed tramadol for pain. You took it as directed. The pain barely budged. You waited an hour, then another. Still nothing meaningful. You are not imagining it — depending on population, up to about 5% of people find that tramadol genuinely does not work the way it should. The reason is genetic, it is well-documented, and it applies to several other common medications as well.

Tramadol Is a Prodrug

Most people assume that when you swallow tramadol, the medication itself relieves pain. It does not — at least not in the way you might expect. Tramadol is a prodrug, meaning it must be converted by your body into its active form before it provides significant opioid-type pain relief.

The active metabolite is called O-desmethyltramadol (also known as M1). M1 is approximately 200 times more potent at the mu-opioid receptor than tramadol itself. The parent compound does have some activity — it inhibits serotonin and norepinephrine reuptake, which provides mild analgesic and mood effects — but the strong pain relief that tramadol is prescribed for comes almost entirely from M1.

The enzyme responsible for this critical conversion is CYP2D6. If your CYP2D6 enzyme has reduced or absent function, you produce very little M1, and tramadol becomes largely ineffective as a pain medication.

CYP2D6 Poor Metabolizers and Tramadol

Depending on population, up to about 5% of people are CYP2D6 poor metabolizers. They carry two non-functional CYP2D6 alleles, meaning the enzyme is essentially absent. For these individuals, tramadol produces minimal opioid-type pain relief at any dose.

The prevalence of CYP2D6 poor metabolizer status varies by population, ranging from about 0.4% up to roughly 5.4% across world populations (Gaedigk et al. 2017). Intermediate metabolizer status is also common — the same CPIC-compiled analysis of world populations found genotypic prevalence ranging from about 0.4% to 11%, depending on ancestry — and these individuals produce some M1, but not enough for full pain relief at standard doses.

If you have experienced symptoms of CYP2D6 poor metabolizer status — medications that seem weaker than expected, requiring higher doses for the same effect, or unexplained treatment failures — the same genotype that explains tramadol non-response likely explains those other experiences as well.

CYP2D6 Ultrarapid Metabolizers: The Opposite Problem

On the other end of the spectrum, about 1 to 2% of Caucasians (and up to 21% in some North African and Middle Eastern populations) are CYP2D6 ultrarapid metabolizers. They carry extra copies of functional CYP2D6 genes and produce M1 at an accelerated rate.

For tramadol, this means too much active metabolite is produced too quickly. The result can be excessive sedation, respiratory depression, nausea, and in rare cases, life-threatening toxicity — even at standard doses. CPIC clinical guidelines recommend avoiding tramadol in ultrarapid metabolizers for this reason.

The Codeine Connection

If this mechanism sounds familiar, it should. Codeine works through the exact same pathway — it is also a CYP2D6 prodrug that must be converted into its active form (morphine) to provide pain relief.

If codeine did not work for you, tramadol likely will not either — for the exact same genetic reason. This connection is clinically important and often overlooked. Many patients who fail codeine are subsequently prescribed tramadol without anyone considering that the same enzyme deficiency explains both failures.

What CPIC Recommends

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published specific guidelines for tramadol based on CYP2D6 metabolizer status. These are Level A recommendations — the highest evidence tier:

• Poor metabolizers: Avoid tramadol. Use an alternative analgesic that is not metabolized by CYP2D6. Tramadol will provide reduced analgesia and treatment failure is expected.
• Intermediate metabolizers: Use tramadol with caution. Consider a reduced starting dose and monitor for adequate pain relief. An alternative analgesic may be needed.
• Normal metabolizers: Use tramadol per standard prescribing. Expected response.
• Ultrarapid metabolizers: Avoid tramadol. Risk of toxicity due to rapid and excessive M1 production. Use an alternative not metabolized by CYP2D6.

Both poor and ultrarapid metabolizers are advised to avoid tramadol entirely — but for opposite reasons.

Alternatives to Consider

If tramadol does not work for you due to CYP2D6 status, several alternative approaches exist. These should always be discussed with your prescriber:

• Non-prodrug opioids: Morphine, oxycodone, and hydromorphone do not require CYP2D6 activation. They work regardless of your CYP2D6 status. However, they have their own risk profiles and pharmacogenomic considerations (e.g., oxycodone involves CYP3A4 metabolism).
• NSAIDs: For many types of pain, NSAIDs are effective alternatives. Note that some NSAIDs (particularly celecoxib) are metabolized by CYP2C9, which has its own genetic variability.
• Non-pharmacological approaches: Physical therapy, nerve blocks, TENS units, and cognitive behavioral approaches to pain management can supplement or replace pharmacological treatment.

The key insight is that tramadol non-response is not a reason to escalate to stronger opioids indiscriminately. It is a reason to switch to a different pathway — one that your genetics can actually utilize.

What Raw DNA Data Can (and Can't) Tell You About CYP2D6

If you have 23andMe, AncestryDNA, or similar raw DNA data, your file contains some of the SNPs that define common CYP2D6 star alleles (*4, *10, *41) — but not the gene deletions (*5), duplications, or CYP2D6/CYP2D7 hybrid alleles that also determine metabolizer status. Those structural changes are invisible to a genotyping array, and they are precisely what separates a poor metabolizer from an ultrarapid one.

So a CYP2D6 status computed from raw data alone is not reliable enough to guide a tramadol decision. DecodeMyBio does not call CYP2D6 from your raw data. Rather than guess, we tell you the truth: CYP2D6 needs a specialized caller that a consumer array does not provide, and we will never invent a result it cannot support. If your tramadol response matters clinically, ask your prescriber about clinical-grade pharmacogenomic testing that includes copy-number analysis — see the full CYP2D6 gene guide for what each phenotype would mean.

Decode's pain & anesthesia results do analyze OPRM1 (opioid receptor sensitivity), COMT (pain perception), BDNF (pain modulation), and ANKK1 — the pain-relevant genes an array can support — and Decode's broader medication safety results follow CPIC guidance across multiple drug classes. Preview your pain & anesthesia results to see exactly what is included.

If you are considering at-home pharmacogenomic testing, be clear-eyed about the boundary: it can explain a great deal about how you handle many medications, but not the CYP2D6 activation step that tramadol and codeine depend on.

What to Do Next

1. Download your raw DNA data if you haven't already — see our upload guide for step-by-step instructions.
2. Get your Decode pain & anesthesia results — they cover OPRM1, COMT, BDNF, and ANKK1. CYP2D6 metabolizer status is not among them, because a genotyping array cannot support it. Learn more →
3. Share your results with your prescriber — review your metabolizer status together at your next appointment. See how it works →